Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
November 24, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Announces Two Presentations at the CTAD 2025 Conference

Annovis attends CTAD 2025 with two presentations highlighting new biomarker data in Alzheimer's and Parkinson's diseases.
November 17, 2025 08:00 ET | Source: Annovis Bio Inc.

Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions in...
July 21, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
June 23, 2025 08:30 ET | Source: Custom Market Insights

[Latest] Global Alzheimer’s Drug Market Size/Share Worth USD 19.3 Billion by 2034 at a 13.03% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, June 23, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Alzheimer’s Drug Market Size, Trends and Insights By Type of Drug...
March 18, 2025 08:48 ET | Source: Today's Marketplace

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s

Today's Marketplace interviews Acumen Pharmaceuticals CEO and Creighton University at the NASDAQ about targeted therapies for Alzheimer's.
July 17, 2024 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024

ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...
April 03, 2023 07:00 ET | Source: Attralus, Inc

Attralus Presents New Preclinical Data on AT-04 and AT-07, Pan-Amyloid Removal Therapeutics Targeting Neurodegenerative Disorders, at AD/PD 2023

AT-04 demonstrated sub nanomolar binding to Aβ, tau and α-synuclein fibrilsAT-04 demonstrated in vivo target engagement and binding to Aβ plaques in the brainAT-07 (AT-04 + Brain Shuttle) demonstrated...
November 17, 2022 07:00 ET | Source: Attralus, Inc

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

SAN FRANCISCO and PHILADELPHIA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with...
April 15, 2022 11:42 ET | Source: UsAgainstAlzheimer's

Alzheimer’s Patient Advocates File FOIA Seeking Answers on Discriminatory Medicare Coverage Decision

Washington, D.C., April 15, 2022 (GLOBE NEWSWIRE) -- Today, UsAgainstAlzheimer’s announced their latest effort to demand answers from the Centers for Medicare and Medicare Services (CMS) about last...